The discovery that mesenchymal stem cells (MSCs) secrete SOD3 may help explain studies in which MSCs have direct anti-oxidant activities both in vivo and in vitro. SOD3 is an antioxidant enzyme that dismutes toxic free radicals produced during inflammatory processes. Therefore MSC production and secretion of active and therapeutically significant levels of SOD3 would further support the use of MSCs as a cellular based antioxidant therapy. The aim of this study was therefore to investigate in vitro if MSC differentiation down the adipogenic, chondrogenic and osteogenic lineages influences the expression of the antioxidant molecule SOD3. Human bone marrow MSCs and their differentiated progeny were cultured under standard conditions and both the SOD3 gene and protein expression examined. Following adipogeneis, cultures demonstrated that both SOD3 protein and gene expression is significantly increased and conversely following chondrogenesis SOD3 protein and gene expression is significantly decreased. Following osteogenesis there was no significant changes in protein or gene expression. This in vitro study describes the initial characterisation of SOD3 expression and secretion by differentiated MSCs. This should help guide further in vivo work establishing the therapeutic and anti-oxidative potential of MSC and their differentiated progeny.
|Translated title of the contribution||Changes in expression of the antioxidant enzyme SOD3 occur upon differentiation of human bone marrow-derived mesenchymal stem cells in vitro|
|Number of pages||9|
|Journal||Stem Cells and Development|
|Publication status||Published - Feb 2012|